NCT05718375招募中2 期
A Multi-center, Randomized, Double-blinded, Placebo-controlled, Parallel Phase IIb Clinical Trial for the Efficacy Assessment and Safety Evaluation by Treating CU01-1001 for 24 Weeks in Type 2 Diabetic Nephropathy Patients With Albuminuria
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 240
- 试验地点
- 1
- 主要终点
- Change rate of urinary albumin/creatinine ratio (UACR) at 24 weeks compared to baseline
研究概览
简要总结
To evaluate the efficacy and safety of CU01-1001 administered for 24 weeks in type 2 diabetic nephropathy patients with albuminuria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male/female patients aged 30 years or above
- •Patients diagnosed as type 2 diabetes prior to screening
- •Patients receiving ACE inhibitors (angiotensin-converting-enzyme inhibitor) or ARB (angiotensin II receptor blockers) for at least 8 weeks prior to screening
- •Patients who experienced albuminuria (albumin to creatinine ratio) 200~1,000 mg/g Cr) at least twice prior to 24weeks including screening results
- •Patients with blood pressure ≤ 140/90mmHg at screening
- •Patients with 25 ≤ GFR (glomerular filtration rate) ≤ 75ml/min/1.73m2 at screening
- •Patients with 6.5% < HbA1c ≤ 9% at screening
排除标准
- •Patients with past medical history of acute renal failure within 12weeks prior to screening; or Increase in SCr ≥ 0.3 mg/dL within 48 hours; or an increase in SCr ≥ 1.5-fold from baseline (the lowest value) within 12 weeks; or urine output <0.5mg/kg/hour for 6 hours
- •NYHA class III~IV
- •Patients with medical history related liver disease and hepatic function as follows: ALT (alanine aminotransferase) or AST (aspartate aminotransferase) >3 X institutional upper limit of normal (ULN), or Total bilirubin >3 X institutional upper limit of normal (ULN)
- •Patients with malabsorption due to organic gastrointestinal disorder or chronic gastroenterological disorders at screening (short-bowel syndrome, active Crohn's disease, and ulcerative colitis, etc.)
- •Patients with acute disease (including infectious diseases) at screening and who are thought to be unable to participate in the clinical study)
- •Within 12 weeks of the informed consent, patients who had the diagnosis and procedures of the following cardiovascular diseases: cardiac failure (NYHA class III and IV), unstable angina pectoris, myocardial infarction, transient ischemic attack, cerebro-vascular accident, history of peripheral vascular disease or coronary artery bypass surgery, and percutaneous transluminal coronary angioplasty
- •Patients with history of alcohol or drug abuse
- •Patients with any allergic reaction to the investigational product or its components
- •Patients who are planning to receive dialysis or renal transplantation within 36 weeks (9 months) in the future
- •Patients who are expected to have lower compliance with protein-limited diets and the use of the study drug
- •Women who are pregnant or breastfeeding a baby
- •Women who are able to become pregnant and do not agree to use acceptable contraception as defined by the protocol; however, women of childbearing potential who have not gone sterility procedures can participate in the study only for negative pregnancy test, and should agree to maintain effective contraception (implants of intrauterine device or intrauterine system, double barrier contraception (condom, diaphragm, sponge or cervical cap with spermicide), oral contraceptives, sterilization, and total abstinence) throughout the study
- •Patients who participated in other clinical study within 12 weeks of the participation in this study
- •Patients who are not eligible for this study participation in the judgment of the principal investigator or sub-investigator
研究组 & 干预措施
CU01-1001 (low dose)
Experimental
1 Tab/3 times/day (CU01-1001 120 mg, Breakfast and Dinner; Placebo 120 mg, Lunch)
干预措施: CU01-1001 (Drug)
CU01-1001 (low dose)
Experimental
1 Tab/3 times/day (CU01-1001 120 mg, Breakfast and Dinner; Placebo 120 mg, Lunch)
干预措施: Placebo (Drug)
CU01-1001 (high dose)
Experimental
1 Tab/3 times/day (CU01-1001 120 mg, Breakfast, Lunch, and Dinner)
干预措施: CU01-1001 (Drug)
Placebo
Placebo Comparator
1 Tab/3 times/day (Placebo, Breakfast, Lunch, and Dinner)
干预措施: Placebo (Drug)
结局指标
主要结局
Change rate of urinary albumin/creatinine ratio (UACR) at 24 weeks compared to baseline
时间窗: Day 0, 24 weeks
Change rate of urinary albumin/creatinine ratio (UACR) at 24 weeks compared to baseline
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
3 期
Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment PatientsType 2 Diabetic NephropathyNCT06606093Daewoong Pharmaceutical Co. LTD.348
已完成
1 期
Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney FunctionMild NephropathyModerate NephropathyDiabetes MellitusNCT00626249Mannkind Corporation36
终止
1 期
Study of REGN1193 in Patients With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT02284425Regeneron Pharmaceuticals72
终止
2 期
A Study of LY2409021 in Participants With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT02111096Eli Lilly and Company174
已完成
2 期
In-patient Study With GSK716155 In Patients With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00354536GlaxoSmithKline60